Lead sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
27 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
27
Trials led
21
Active
7,286
Total enrollment
40
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
13
Phase 2
5
Phase 3
8
Phase 4
1
Trials by status
Not yet recruiting
8
Recruiting
13
Completed
5
Unknown
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) InhibitorBMI ≥22.5Ph 3Not yet recruiting912
Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without DiabetesBMI ≥28Ph 3Recruiting825
A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes MellitusBMI 19-40Ph 3Recruiting800
Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese AdultsBMI ≥28Ph 3Not yet recruiting780
Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 DiabetesBMI 18.5-35Ph 3Completed494
Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese PatientsBMI ≥28Ph 3Recruiting460
Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without DiabetesBMI ≥28Ph 2Recruiting372
Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes MellitusBMI 22.5-40Ph 3Recruiting360
To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes MellitusBMI 22.5-40Ph 2Completed324
Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes MellitusBMI ≥28Ph 2Recruiting240
A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise AloneBMI ≥22.5Ph 3Recruiting240
A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or MetforminHbA1c 7.5-10.5%Ph 2Recruiting216
Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese AdultsBMI ≥28Ph 2Unknown180
A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and WarfarinBMI 24-35Ph 1Recruiting111
Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.BMI ≥50Ph 1Completed68
Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and DigoxinBMI 24-35Ph 1Not yet recruiting42
A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic ImpairementBMI ≥50Ph 1Recruiting40
A Drug-Drug Interaction (DDI) Study of HDM1002 With Rifampicin and Itraconazole in Healthy SubjectsBMI 19-32Ph 1Not yet recruiting40
A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy SubjectsBMI 19-30Ph 1Not yet recruiting33
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.BMI 19-30Ph 1Not yet recruiting30
A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy ParticipantsBMI 19-35Ph 1Not yet recruiting30
A Study To Characterize Mass Balance Of [14C] HDM1002 in Chinese Healthy SubjectsBMI 19-32Ph 1Recruiting10